Form 4 for STLN Starling Oncology, Inc.
Accepted 2022-03-23 00:00:00 ET · period of report 2022-03-21 · accession 0001628280-22-007101 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-23 | 2022-03-21 | STLN | Hively Brad | CEO, Dir | A - Grant | $0.00 | +108.5K | 461.9K | +31% | $0 |
| D | 2022-03-23 | 2022-03-21 | STLN | Hively Brad | CEO, Dir | A - Grant | $0.00 | +88.1K | 88.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2022-03-21 | A | A | 108,469 | $0.00 | 461,919 | D | — | — | (F1) Represents restricted stock units ("RSUs") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. (F2) The reporting person's last filing incorrectly reported 363,450 total holdings instead of 353,450 total holdings. |
| 2 | Derivative | Stock Option (right to buy) | 2022-03-21 | A | A | 88,090 | $0.00 | 88,090 | D | $7.09 · — to 2032-03-21 | 88,090 Common stock | (F3) The stock options vest in four equal annual installments on each of the first four anniversaries of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |